Empowered Funds LLC Raises Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Empowered Funds LLC boosted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 229,485 shares of the company's stock after buying an additional 11,149 shares during the period. Empowered Funds LLC owned approximately 0.50% of Pacira BioSciences worth $4,323,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in shares of Pacira BioSciences by 129.4% in the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company's stock valued at $74,681,000 after acquiring an additional 2,799,434 shares during the period. Assenagon Asset Management S.A. lifted its stake in Pacira BioSciences by 314.4% during the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company's stock worth $8,324,000 after purchasing an additional 419,656 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company's stock valued at $5,955,000 after buying an additional 288,662 shares in the last quarter. PDT Partners LLC acquired a new stake in Pacira BioSciences in the third quarter valued at about $3,469,000. Finally, Impax Asset Management Group plc grew its holdings in shares of Pacira BioSciences by 81.0% during the 3rd quarter. Impax Asset Management Group plc now owns 470,603 shares of the company's stock valued at $7,083,000 after purchasing an additional 210,576 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on PCRX. Barclays lowered their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a report on Tuesday, November 12th. HC Wainwright reissued a "buy" rating and set a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC lifted their target price on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $22.78.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX traded down $1.09 during midday trading on Friday, reaching $25.44. The company's stock had a trading volume of 615,935 shares, compared to its average volume of 924,745. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The stock has a market capitalization of $1.17 billion, a P/E ratio of -12.53 and a beta of 0.80. The firm has a 50 day moving average price of $22.00 and a 200-day moving average price of $18.15. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.